# **1** Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies

### 2 to SARS-CoV-2

- 3 Douglas F. Lake<sup>1\*#</sup>, Alexa J. Roeder<sup>1\*</sup>, Erin Kaleta<sup>2</sup>, Paniz Jasbi<sup>3</sup>, Kirsten Pfeffer<sup>1</sup>,
- 4 Calvin Koelbel<sup>1</sup> Sivakumar Periasamy<sup>4,5</sup> Natalia Kuzmina<sup>4,5</sup> Alexander Bukreyev<sup>4,5,6</sup>,
- 5 Thomas E. Grys<sup>2</sup>, Liang Wu<sup>7</sup>, John R Mills<sup>7</sup>, Kathrine McAulay<sup>2</sup>, Maria Gonzalez-Moa<sup>8</sup>,
- 6 Alim Seit-Nebi<sup>8</sup>, and Sergei Svarovsky<sup>8</sup>
- 7
- 8 Affiliations:
- 9 1. School of Life Sciences, Arizona State University, Tempe AZ, USA
- 10 2. Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology,

11 Scottsdale, AZ, USA

- 12 3. College of Health Solutions, Arizona State University, Phoenix AZ, USA
- Department of Pathology, University of Texas Medical Branch at Galveston,
   Galveston, TX USA
- 15 5. Galveston National Laboratory, University of Texas Medical Branch at Galveston,
- 16 Galveston, TX USA
- Department of Microbiology and Immunology University of Texas Medical Branch
   at Galveston, Galveston, TX USA
- 19 7. Mayo Clinic Rochester, Department of Laboratory Medicine and Pathology,
- 20 Rochester, MN USA
- 21 8. Axim Biotechnologies Inc, San Diego, CA USA
- 22 \*Co-first authors
- 23
- 24 #Address correspondence to Douglas F. Lake, <u>douglas.lake@asu.edu</u>

25

26 Word Count: 2498

27

## 28 Abstract:

Background: After receiving a COVID-19 vaccine, most recipients want to know if they 29 30 are protected from infection and for how long. Since neutralizing antibodies are a 31 correlate of protection, we developed a lateral flow assay (LFA) that measures levels of 32 neutralizing antibodies from a drop of blood. The LFA is based on the principle that 33 neutralizing antibodies block binding of the receptor-binding domain (RBD) to 34 angiotensin-converting enzyme 2 (ACE2). 35 Methods: The ability of the LFA was assessed to correctly measure neutralization of 36 sera, plasma or whole blood from patients with COVID-19 using SARS-CoV-2 37 microneutralization assays. We also determined if the LFA distinguished patients with 38 seasonal respiratory viruses from patients with COVID-19. To demonstrate the 39 usefulness of the LFA, we tested previously infected and non-infected COVID-19 40 vaccine recipients at baseline and after first and second vaccine doses. 41 Results: The LFA compared favorably with SARS-CoV-2 microneutralization assays 42 with an area under the ROC curve of 98%. Sera obtained from patients with seasonal 43 coronaviruses did not show neutralizing activity in the LFA. After a single mRNA 44 vaccine dose, 87% of previously infected individuals demonstrated high levels of 45 neutralizing antibodies. However, if individuals were not previously infected only 24% 46 demonstrated high levels of neutralizing antibodies after one vaccine dose. A second 47 dose boosted neutralizing antibody levels just 8% higher in previously infected 48 individuals, but over 63% higher in non-infected individuals. 49 **Conclusions:** A rapid, semi-quantitative, highly portable and inexpensive neutralizing 50 antibody test might be useful for monitoring rise and fall in vaccine-induced neutralizing 51 antibodies to COVID-19.

52

## 53 KEYWORDS

54 Neutralizing Antibodies, COVID-19, SARS-CoV-2, Lateral Flow Assay, RBD, ACE2

# 55 INTRODUCTION

56	Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) causes
57	COVID-19 and originated in Wuhan, China in December 2019 [1–3]. Vaccines continue
58	to be tested [4,5] with the goal of preventing COVID-19 via induction of neutralizing
59	antibodies (NAbs) and anti-viral T cells. Vaccine trials show that RNA vaccines elicit
60	protective immunity, but durability of natural and vaccine-induced immunity is not fully
61	known [5]. Several groups reported that up to one-third of serum samples from
62	individuals who recovered from COVID-19 do not neutralize SARS-CoV-2 [6–8].
63	Whether previously infected or vaccinated, it is informative for individuals to learn if they
64	generated high levels of NAbs so that they can resume normal activities without fear of
65	re-infection and transmitting the virus [9–11].
66	Viral neutralization assays measure antibodies that block infection of host cells.
67	The gold standard of neutralization for SARS-CoV-2 measures reduction of viral
68	plaques or foci in microneutralization assays. These assays are slow, laborious, require
69	highly trained personnel and a BSL3 facility. Another challenge is that neutralization
70	assays require careful titration of virus and depend on host cells for infection, both of
71	which add variability to the assay. These limitations prevent use of SARS-CoV-2
72	neutralization assays for clinical applications.
73	SARS-CoV-2 uses receptor binding domain (RBD) on spike protein to bind
74	angiotensin converting enzyme 2 (ACE2) on host cells; RBD appears to be the principal
75	neutralizing domain [12,13]. Using this knowledge, we developed a lateral flow assay
76	(LFA) that measures levels of NAbs which block RBD from binding to ACE2. Other
77	groups have developed RBD-ACE2-based competition ELISAs[18,19] but none have

78	developed a rapid, highly portable, semi-quantitative test that can easily be incorporated
79	into clinical settings or research studies where traditional laboratory or neutralization
80	tests are not practical.
81	
82	MATERIALS AND METHODS
83	Human Subjects and Samples
84	Serum and finger-stick blood samples were collected for this study under an
85	Arizona State University institutional review board (IRB)-approved protocol
86	#0601000548 and Mayo Clinic IRB protocol #20-004544. Serum samples obtained
87	from excess clinical samples at Mayo Clinic were left over from normal workflow.
88	COVID-19 samples ranged from 3 to 84 days post PCR positive result.
89	Twenty-seven control serum samples from patients with non-COVID-19
90	respiratory illnesses as determined by the FilmArray Respiratory Panel 2 (Biofire
91	Diagnostics) were collected from patients from 2/14/17 – 4/6/20 as part of routine
92	clinical workflow. All residual clinical samples were stored at 2-8°C for up to 7 days, and
93	frozen at -80°C thereafter.

94

# 95 SARS-CoV-2 Microneutralization Assay

A microneutralization assay was performed using a recombinant SARS-CoV-2 expressing mNeonGreen (SARS-CoV-2ng) as previously described [16]. Inhibitory concentrations for which 50% of virus is neutralized by serum antibodies (IC<sub>50</sub> values) were obtained on a set of 38 COVID-19 sera. Sixty  $\mu$ I aliquots of SARS-CoV-2ng were pre-incubated for 1 h in 5% CO<sub>2</sub> at 37°C with 60 $\mu$ I 2-fold serum dilutions in cell culture

101 media, and 100µl were inoculated onto Vero-E6 monolayers in black polystyrene 96-102 well plates with clear bottoms (Corning) in duplicate. The final amount of the virus was 103 200 PFU/well, the starting serum dilution was 1:20 and the end dilution was 1:1280 104 unless an IC<sub>50</sub> was not reached in which case serum was diluted to 1:10240. Cells were 105 maintained in Minimal Essential Medium (ThermoFisher Scientific) supplemented by 2% 106 FBS (HyClone) and 0.1% gentamycin in 5% CO<sub>2</sub> at 37°C. After 2 days of incubation, 107 fluorescence intensity of infected cells was measured at 488 nm using a Synergy 2 Cell Imaging Reader (Biotek). Signal was normalized to virus alone with no serum added 108 109 and reported as percent neutralization. IC<sub>50</sub> was calculated with GraphPad Prism 6.0 110 software. Work was performed in a BSL-3 biocontainment laboratory of the University of 111 Texas Medical Branch, Galveston, TX. 112 113 Serologic Antibody Assay

114 The Ortho Vitros Anti-SARS-CoV-2 IgG test (Ortho Vitros test) was performed on 115 an Ortho Clinical Diagnostics Vitros 3600 Immunodiagnostics System at the Mayo 116 Clinic. This assay is approved for clinical testing under FDA Emergency Use 117 Authorization to qualitatively detect antibody to the S1 subunit of SARS-CoV-2 spike 118 protein. Results are reported as reactive (S/CO  $\geq$  1.0) or nonreactive (S/CO <1.0). 119 Specimens were tested within 7 days of collection and stored at 2-8°C. The same 38 120 serum samples were run in the Ortho Vitros test, microneutralization assay, and the 121 LFA.

122

#### 124 Lateral Flow Neutralizing Antibody Assay

125 The Lateral Flow NAb assay was developed to measure levels of antibodies that 126 compete with ACE2 for binding to RBD. The LFA single port cassette (Empowered 127 Diagnostics) contains a test strip composed of a sample pad, blood filter, conjugate pad, 128 nitrocellulose membrane striped with test and control lines, and an absorbent pad (Axim 129 Biotechnologies Inc). The LFA also contains a control mouse antibody conjugated to 130 red gold nanospheres and corresponding anti-mouse IgG striped at the control line. LFAs were run at room temperature on a flat surface for 10 minutes prior to 131 132 reading results. To perform the test, 6.7µl of serum or 10µl whole blood were added to 133 the sample port followed by 60µl of chase buffer. After 10 minutes, densities of both test 134 and control lines were recorded in an iDetekt RDS-2500 density reader. 135 The test leverages the interaction between RBD-conjugated green-gold 136 nanoshells (Nanocomposix) that bind ACE2 at the test line when RBD-neutralizing 137 antibodies (RBD-NAbs) are absent or low. Test line density is inversely proportional to 138 RBD-NAbs present within the sample. As a semi-guantitative test, the results of the LFA 139 can be interpreted using a scorecard or a densitometer. A red line across from the "C" 140 indicates that the test ran properly. An absent or faint test line indicates high levels of 141 RBD-NAbs, whereas a dark test line suggests low or lack of RBD-NAbs.

142

Precision testing was performed using sera from one highly, and one nonneutralizing donor in replicates of 10. Density values were recorded as above and %CVs calculated using the formula: (Standard Deviation/Mean) \* 100%.

146

## 147 Data Analysis

148 Pearson's correlation (r) was conducted to assess the strength and significance of 149 associations between the LFA, the Ortho Vitros test and IC<sub>50</sub> values. Regression analysis 150 using IC<sub>50</sub> values evaluated consistency [14] while Bland-Altman plots assessed 151 agreement and bias [17,18]. Correlation analysis was conducted using IBM SPSS. For 152 two-group analysis,  $IC_{50}$  values corresponding to >240 were categorized as titer of >1:320 153 (neutralizing), whereas IC<sub>50</sub> values  $\leq$ 240 were categorized as  $\leq$ 1:160 (low/non-154 neutralizing). Receiver operating characteristic (ROC) analysis was performed to assess 155 accuracy, sensitivity, and specificity of the LFA and Ortho Vitros tests in assessing 156 neutralization; optimal cutoffs for each method were established to maximize area under 157 curve (AUC) [19,20]. ROC analysis was conducted using R language in the RStudio 158 environment (version 3.6.2; RStudio PBC). All analyses were conducted using raw values; 159 data were not normalized, transformed, or scaled.

160

161 RESULTS

As shown at the bottom in **Figure 1A**, serum containing high levels of NAbs results in a weak or ghost test line because NAbs bind RBD on green-gold beads, preventing RBD from binding to the ACE2 receptor at the test line. Serum with low levels of NAbs results in a strong test line because little to no antibodies prevent RBD on beads from binding to ACE2. **Figure 1B** demonstrates results of the test using COVID-19 sera with different levels of NAbs.



- 170 **Figure 1.** (A) Schematic of Neutralization LFA. Below each graphic is a representative
- 171 image of a lateral flow strip demonstrating actual line density. Addition of non-
- 172 COVID19-immune serum or plasma (*top*) does not block binding of RBD-beads (green
- 173 particles) to ACE2 resulting in the RBD-bead–ACE2 complex creating a visible line.
- 174 Addition of patient serum with moderate titer NAbs to the sample pad creates a weak
- 175 line (*middle*). Addition of patient serum with high titer NAbs (> 1:640) blocks binding of

176 RBD-beads to ACE2 such that no line is observed at the test location on the strip 177 (bottom). Red control line represents capture of a mouse monoclonal antibody coupled 178 to red beads. (B) Scorecard for measuring levels of NAbs . Red control line across 179 from the "C" on the cassette indicates that the test ran properly and the green test line 180 across from the "T" can be used to measure the ability of plasma or serum to block RBD 181 on gold nanoshells from binding to ACE2. (0) represents patient serum producing a 182 visually non-existent line with density units of 10,095 and an  $IC_{50}$ >500 ( $IC_{50}$ =1151); (1) 183 represents patient serum with a line density of 132,503 and an  $IC_{50}$  of 396; (2) 184 represents patient serum with a line density of 239,987 and an  $IC_{50}$  of 243; (3) 185 represents patient serum with a line density of 485,665 and an IC<sub>50</sub> of 96. 186 187 To support the application of the LFA to measure NAb levels to SARS-CoV-2, we 188 tested 38 serum samples that were assigned IC<sub>50</sub> values in a SARS-CoV-2 189 microneutralization assay [16]. The experiment was performed in a blinded manner 190 such that personnel running either the LFA or the microneutralization assay did not 191 know the results of the comparator test. When line densities from the LFA were plotted 192 against  $IC_{50}$  values determined in the microneutralization assay, serum samples with 193 strong neutralization activity demonstrated low line densities; this indicates that NAbs 194 inhibited RBD from binding to ACE2 (Figure 2).



195

Figure 2. Comparison of RBD-ACE2 competition LFA density values with IC<sub>50</sub> values
determined in a SARS-CoV-2 microneutralization assay on 38 samples (collected 3 to
90 days after PCR positive result). Ranges of IC<sub>50</sub> values are shown on the X-axis
plotted against LFA line density units on the Y-axis.

200

201

Next, we determined if the LFA detected neutralization activity in serum samples collected from patients with other PCR-confirmed respiratory viruses including seasonal coronaviruses (**Figure 3A**) and for serum samples collected prior to December 2019 (**Figure 3B**). Neither seasonal respiratory virus sera, nor pre-December 2019 samples showed neutralizing activity.



Sera from seasonal respiratory virus infections





217 We then compared both the Ortho Vitros test and our LFA to sera with  $IC_{50}$  values 218 determined in the SARS-CoV-2 microneutralization assay using 38 COVID-19 sera. To 219 assess agreement between our LFA and the Ortho Vitros test, density units from the LFA 220 and values from the Ortho test were regressed onto IC<sub>50</sub> values (Supplemental Figure 221 S1). 222 223 В Α Ortho LFA 45 800 **Thousands Ortho values** LFA values 600 30 y = 0.0168x + 12.567400 R<sup>2</sup> = 0.2725 -452.15x + 462047 15  $R^2 = 0.5187$ 200 0 0 0.5 1 1.5 2 0.5 1.5 2 0 0 1 Thousands Thousands

Serum titer (IC<sub>50</sub>)

Serum titer (IC<sub>50</sub>)



228

LFA values accounted for roughly 52% of observed variance in IC<sub>50</sub> values, while the Ortho Vitros test accounted for approximately 27% of IC<sub>50</sub> variance. LFA showed significant negative correlation with IC<sub>50</sub> values (r = -0.720, p < 0.001), while the Ortho Vitros test values showed a significant positive correlation to IC<sub>50</sub> values (r = 0.522, p =0.001). Additionally, the LFA and Ortho Vitros test values correlated with each other (r =-0.572, p < 0.001).

To evaluate bias, mean differences and 95% confidence intervals (CIs) were calculated and plotted alongside limits of agreement (**Figure 4**). Both LFA and Ortho

- 237 Vitros test values showed strong agreement with titer, although the Ortho Vitros test
- showed a tendency to underestimate neutralizing capacity while the LFA method showed
- no bias.
- 240





- 246
- 247

ROC analysis was performed to assess the ability of the LFA and the Ortho Vitros test to classify low/non-neutralizing (Neg, <1:160), and highly neutralizing groups ( $\geq$ 1:320) (**Figure 5**). As shown in **Figure 5B** and **5D**, the LFA misclassified one non-neutralizing sample (Neg, <1:160) as neutralizing ( $\geq$ 1:320) which the Ortho Vitros test also misclassified as neutralizing. The Ortho test also incorrectly classified five additional neutralizing samples as non-neutralizing.

Our LFA showed high accuracy for classification of neutralizing samples (AUC = 0.978), while the Ortho Vitros test showed modest accuracy (AUC = 0.856). Notably, while both methods showed roughly 90% sensitivity, the Ortho Vitros test showed only 70%

specificity. In contrast, the LFA showed perfect specificity (100%) in this analysis of 38samples.

Optimal cutoffs were computed to maximize AUC. For the LFA, density unit values
 below 263,000 classify samples as neutralizing and correspond to titers ≥1:320. Density
 values above this LFA cutoff classify samples in the non-neutralizing group. For the Ortho
 Vitros test, values between 0 and 23.3 were representative of non-neutralizing capacity,
 whereas values above 23.3 were reflective of the neutralizing group.



265	Figure 5. (A) Univariate ROC analysis of Ortho Vitros Anti-SARS-CoV-2 IgG test for
266	discrimination of neutralizing samples (≥1:320) [AUC: 0.856, 95% CI: 0.697-0.953,
267	sensitivity = 0.9, specificity = 0.7]. (B) Box plot of Ortho Vitros Anti-SARS-CoV-2 IgG test
268	values between neutralizing ( $\geq$ 1:320) and non-neutralizing (Neg—1:160) groups. (C)
269	Univariate ROC analysis of LFA for discrimination of neutralizing samples (≥1:320) [AUC:
270	0.978, 95% CI: 0.908—1.0, sensitivity = 0.9, specificity = 1.0]. (D) Box plot of LFA values
271	between neutralizing ( $\geq$ 1:320) and non-neutralizing (Neg—1:160) groups.
272 273	Precision studies were performed on replicate samples (n=10) and showed a CV

of ~9% from a serum sample in the high neutralizing range and ~6% CV in a serum

- sample from the low neutralizing range (Supplemental Table 1).
- 276

Low Neutralizing Range			
10 min	с	т	T/C Ratio at 10 min
1	503764	932173	1.850416068
2	484316	944154	1.949458618
3	509424	902070	1.770764628
4	441318	840951	1.905544301
5	484558	990076	2.043255916
6	472319	906922	1.920147189
7	519936	971429	1.868362645
8	495254	992223	2.00346287
9	467545	816303	1.745934616
10	534262	941643	1.762511652
Average	491269.6	923794.4	1.88198585
STD Dev	25849.98843	55966.17114	0.096780674
%CV	5.26	6.06	5.14

High Neutralizing Range			
10 min	с	Т	T/C Ratio at 10 min
1	415421	232022	0.558522559
2	404845	286183	0.706895232
3	419873	261146	0.621964261
4	417475	248141	0.594385293
5	409970	263808	0.64348123
6	397812	294120	0.739344213
7	409681	237096	0.578733209
8	412275	242082	0.587185738
9	373751	222959	0.596544223
10	373339	224335	0.600888201
Average	403444.2	251189.2	0.622794416
STD Dev	16097.74032	23457.01668	0.055137744
%CV	3.99	9.34	8.85

277

278 Supplemental Table 1. Precision study using one Low Neutralizing Range serum 279 sample and one High Neutralizing Range serum sample in replicates of ten. Low range 280 neutralization is defined as densities from 370,000 - 800,000. The used for precision 281 analysis was from an individual who recovered from COVID-19 but did not neutralize 282 virus in the microneutralization assay ( $IC_{50} < 20$ ). High neutralization range samples are 283 defined as densities from 10,000 – 369,999. This sample has an IC50 of 248. 284 285 Precision studies were performed on replicate samples (n=10) and showed a CV 286 of ~9% from a serum sample in the high neutralizing range and ~6% CV in a serum 287 sample from the low neutralizing range (Supplemental Table 1).

288	
289	Since NAb levels may be considered correlates of protection, we tested sera
290	from RNA vaccine recipients (mRNA-1723 and BNT162b2) in "previously infected" and
291	"not previously infected" individuals using finger-stick blood in the rapid LFA (Figure 6).
292	In previously infected individuals at baseline (within 3 months of PCR-based diagnosis),
293	38% demonstrated high levels of NAbs. After the first vaccine dose, 87% of previously
294	infected individuals demonstrated high NAb levels, while only 24% of not previously
295	infected individuals developed high levels of NAbs. After the second vaccine dose,
296	levels of NAbs increased to 95% in the previously infected cohort, while NAb levels
297	second vaccine dose is important for bighest levels of NAbs
290	second vaccine dose is important for highest levels of tables.



## 301 Figure 6. NAb levels in prior infection and vaccine-induced individuals. (A)

Baseline indicates within one week of first vaccine dose; Post-1<sup>st</sup> Dose indicates withing one week of 2<sup>nd</sup> vaccine dose; Post 2<sup>nd</sup> Dose indicates 10-20 days after 2<sup>nd</sup> vaccine dose. High and Low indicates density ranges of Test lines shown in (B). Densities were read in a reader as described in Methods. Serum titers that correspond to high range densities are >1:1280 to ≥1:160. Serum titers corresponding to low range densities are 307 <1:160.

308

#### 309 DISCUSSION

310 We developed a rapid test that measures levels of NAbs in serum and whole 311 blood. As shown in **Figure 2**, the LFA correlates well with serologic titers determined 312 using a SARS-CoV-2 microneutralization assay, especially when serum sample IC<sub>50</sub> 313 values are >250. Advantages of the LFA test are that it can be inexpensively and 314 rapidly deployed to determine levels of NAbs in vaccine recipients. Moreover, the test 315 can be used longitudinally to evaluate duration of protective immunity in naturally 316 infected and vaccinated individuals-many more than could ever be evaluated using 317 BSL2 or BSL3-based neutralization assays.

318

The LFA and Ortho Vitros test showed a significant correlation with each other (*r* = -0.572, *p* < 0.001), displaying good linear relation (r = -0.720, p < 0.001)[21]. The LFA accounts for 52% of observed IC<sub>50</sub> variance ( $R^2 = 0.5187$ ), while the Ortho Vitros test accounts for 27% ( $R^2 = 0.2725$ ). Although absolute quantitation demands an excellent coefficient of determination ( $R^2 \ge 0.99$ )[22], variables with  $R^2 \ge 0.5$  are highly predictive in univariate regression models while measures with  $R^2 < 0.5$  are recommended for use in multivariate models with complementary measures to increase predictive accuracy 326 [23,24]. Bland-Altman analysis (**Figure 4**) showed the Ortho Vitros test to be prone to 327 underestimation of IC<sub>50</sub> values, while the LFA method did not exhibit over- or 328 underestimation bias. Furthermore, across mean values for both methods, the LFA 329 showed discrete differential values while the Ortho Vitros test struggled to differentiate 330 high neutralizing samples.

331

332 Using our rapid test to measure NAbs in previously infected vaccine recipients and those who were not infected agrees with other studies in BSL3 facilities using 333 334 serum from venipuncture blood [5,25–29]. Natural infection may not elicit high levels of 335 NAbs [6-8], but a first dose of vaccine induces high levels of NAbs in the majority of 336 recipients similar to 2 doses of vaccine in non-previously infected individuals. 337 suggesting natural infection primes the immune system[30]. In naïve individuals, a 338 single dose of vaccine elicits high NAb levels (Titers >1:160) in only 24% of vaccine 339 recipients, leaving 76% of vaccine recipients with titers lower than 1:160 which would 340 not qualify for convalescent plasma donation according to FDA memo of March 9,2021. 341 After a second vaccine dose, the LFA indicated high levels of NAbs in 87% of 342 recipients, identical to levels observed in previously infected individuals after the first vaccine dose. These findings might suggest that a booster (3rd vaccine dose) in non-343 344 infected individuals could induce the highest levels of NAbs in the most people. 345

Limitations of the LFA are that it uses only the RBD portion of spike protein. Although the vast majority of reports indicate that the principle neutralizing domain is the RBD portion of spike protein, mAbs have been reported that neutralize SARS-CoV-2 by

349 binding to the N-terminal domain of spike protein [31,32]. Also, since the spike protein 350 assumes multiple conformations during viral binding and entry [33], neutralizing 351 epitopes exist on the guaternary structure of spike [32]. Although RBDs on the 352 nanoparticles may associate, it is not known if they assume a native conformation. 353 Other limitations are the binary nature of this data analysis (high and low 354 neutralizing) of a continuous assay. NAb levels should be evaluated longitudinally to 355 assess rise and fall in NAb levels; this rapid test is well-suited for that role. Another 356 limitation is that the LFA does not differentiate high affinity anti-RBD NAbs from an 357 abundance of lower affinity anti-RBD NAbs. 358 This test may prove useful in monitoring COVID-19 vaccine recipients as a 359 correlate of protection. It would be logistically difficult to obtain a tube of blood from 360 every vaccine recipient for BSL3 work. However, since this LFA requires only a drop of 361 blood, individual use of this test might lead to more comprehensive longitudinal 362 monitoring of protective humoral immunity and indicate when boosters might be 363 required. 364 365 366 AUTHOR CONTRIBUTIONS 367 DL. SS and AS-N developed the LFA. AJ performed the experiments and interpreted 368 the results. PJ performed statistical analysis. EK, TG and KM contributed samples. 369 CK, AJ and KP tested vaccine recipients and interpreted results. SP, NK and AB 370 performed SARS-CoV-2 microneutralization assays and interpreted results LW and JM 371 contributed samples for preliminary experiments. MM-G designed the strip layout and

372 produced the strips for the vaccine study.

# 373

- 374 CONFLICTS OF INTEREST STATEMENT
- 375 DL and SS are co-founders of Sapphire, the research division of Axim Biotech. SS, MM-
- 376 G and AS-N are employees of Axim Biotech. Other authors have no conflicts regarding
- this work.
- 378
- 379 FUNDING
- 380 This study was funded in part by Axim Biotech, San Diego, CA
- 381

# 382 **References**

- 383 [1] I. Ghinai, T.D. McPherson, J.C. Hunter, H.L. Kirking, D. Christiansen, K. Joshi, R. Rubin, S. 384 Morales-Estrada, S.R. Black, M. Pacilli, M.J. Fricchione, R.K. Chugh, K.A. Walblay, N.S. 385 Ahmed, W.C. Stoecker, N.F. Hasan, D.P. Burdsall, H.E. Reese, M. Wallace, C. Wang, D. 386 Moeller, J. Korpics, S.A. Novosad, I. Benowitz, M.W. Jacobs, V.S. Dasari, M.T. Patel, J. 387 Kauerauf, E.M. Charles, N.O. Ezike, V. Chu, C.M. Midgley, M.A. Rolfes, S.I. Gerber, X. Lu, S. 388 Lindstrom, J.R. Verani, J.E. Layden, S. Brister, K. Goldesberry, S. Hoferka, D. Jovanov, D. 389 Nims, L. Saathoff-Huber, C. Hoskin Snelling, H. Adil, R. Ali, E. Andreychak, K. Bemis, M. 390 Frias, P. Quartey-Kumapley, K. Baskerville, E. Murphy, E. Murskyi, Z. Noffsinger, J. Vercillo, 391 A. Elliott, U.S. Onwuta, D. Burck, G. Abedi, R.M. Burke, R. Fagan, J. Farrar, A.M. Fry, A.J. 392 Hall, A. Haynes, C. Hoff, S. Kamili, M.E. Killerby, L. Kim, S.A. Kujawski, D.T. Kuhar, B. Lynch, 393 L. Malapati, M. Marlow, J.R. Murray, B. Rha, S.K.K. Sakthivel, S.E. Smith-Jeffcoat, E. Soda, L. 394 Wang, B.L. Whitaker, T.M. Uyeki, First known person-to-person transmission of severe 395 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA, The Lancet. 395 (2020) 396 1137-1144. https://doi.org/10.1016/S0140-6736(20)30607-3.
- C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu,
  J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R.
  Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel
  coronavirus in Wuhan, China, The Lancet. 395 (2020) 497–506.
- 401 https://doi.org/10.1016/S0140-6736(20)30183-5.
- 402 [3] R. Li, S. Pei, B. Chen, Y. Song, T. Zhang, W. Yang, J. Shaman, Substantial undocumented
  403 infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2), Science.
  404 368 (2020) 489–493. https://doi.org/10.1126/science.abb3221.
- 405 [4] F.P. Polack, S.J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J.L. Perez, G. Pérez
   406 Marc, E.D. Moreira, C. Zerbini, R. Bailey, K.A. Swanson, S. Roychoudhury, K. Koury, P. Li,
- 407 W.V. Kalina, D. Cooper, R.W. Frenck, L.L. Hammitt, Ö. Türeci, H. Nell, A. Schaefer, S. Ünal,

D.B. Tresnan, S. Mather, P.R. Dormitzer, U. Şahin, K.U. Jansen, W.C. Gruber, Safety and
Efficacy of the BNT162b2 mRNA Covid-19 Vaccine, N. Engl. J. Med. 383 (2020) 2603–2615.
https://doi.org/10.1056/NEJMoa2034577.

- 411 [5] A.T. Widge, N.G. Rouphael, L.A. Jackson, E.J. Anderson, P.C. Roberts, M. Makhene, J.D.
- 412 Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers, A.B. McDermott, B. Flach, B.C. Lin, N.A.
- 413 Doria-Rose, S. O'Dell, S.D. Schmidt, K.M. Neuzil, H. Bennett, B. Leav, M. Makowski, J.
- 414 Albert, K. Cross, V.-V. Edara, K. Floyd, M.S. Suthar, W. Buchanan, C.J. Luke, J.E.
- Ledgerwood, J.R. Mascola, B.S. Graham, J.H. Beigel, Durability of Responses after SARSCoV-2 mRNA-1273 Vaccination, N Engl J Med. (2020) 4.
- 417 [6] D.F. Robbiani, C. Gaebler, F. Muecksch, J.C.C. Lorenzi, Z. Wang, A. Cho, M. Agudelo, C.O.
- 418Barnes, A. Gazumyan, S. Finkin, T. Hagglof, T.Y. Oliveira, C. Viant, A. Hurley, H.-H.419Hoffmann, K.G. Millard, R.G. Kost, M. Cipolla, K. Gordon, F. Bianchini, S.T. Chen, V. Ramos,
- R. Patel, J. Dizon, I. Shimeliovich, P. Mendoza, H. Hartweger, L. Nogueira, M. Pack, J.
  Horowitz, F. Schmidt, Y. Weisblum, E. Michailidis, A.W. Ashbrook, E. Waltari, J.E. Pak, K.E.
- 422 Huey-Tubman, N. Koranda, P.R. Hoffman, A.P. West, C.M. Rice, T. Hatziioannou, P.J.
- 423Bjorkman, P.D. Bieniasz, M. Caskey, M.C. Nussenzweig, Convergent Antibody Responses to424SARS-CoV-2 Infection in Convalescent Individuals, Immunology, 2020.
- 425 https://doi.org/10.1101/2020.05.13.092619.
- [7] J.A. Juno, H.-X. Tan, W.S. Lee, A. Reynaldi, H.G. Kelly, K. Wragg, R. Esterbauer, H.E. Kent, C.J.
  Batten, F.L. Mordant, N.A. Gherardin, P. Pymm, M.H. Dietrich, N.E. Scott, W.-H. Tham, D.I.
  Godfrey, K. Subbarao, M.P. Davenport, S.J. Kent, A.K. Wheatley, Immunogenic profile of
  SARS-CoV-2 spike in individuals recovered from COVID-19, Infectious Diseases (except
  HIV/AIDS), 2020. https://doi.org/10.1101/2020.05.17.20104869.
- [8] F. Wu, A. Wang, M. Liu, Q. Wang, J. Chen, S. Xia, Y. Ling, Y. Zhang, J. Xun, L. Lu, S. Jiang, H.
  Lu, Y. Wen, J. Huang, Neutralizing antibody responses to SARS-CoV-2 in a COVID-19
  recovered patient cohort and their implications, MedRxiv Prepr. (2020) 20.
  https://doi.org/10.1101/2020.03.30.20047365.
- 435 [9] Z. Han, F. Battaglia, S.R. Terlecky, Discharged COVID-19 Patients Testing Positive Again for
  436 SARS-CoV-2 RNA: A Minireview of Published Studies from China, J. Med. Virol. (2020)
  437 jmv.26250. https://doi.org/10.1002/jmv.26250.
- 438 [10] G. Ye, Z. Pan, Y. Pan, Q. Deng, L. Chen, J. Li, Y. Li, X. Wang, Clinical characteristics of severe
  439 acute respiratory syndrome coronavirus 2 reactivation, J. Infect. 80 (2020) e14–e17.
  440 https://doi.org/10.1016/j.jinf.2020.03.001.
- [11] V.T. Hoang, T.L. Dao, P. Gautret, Recurrence of positive SARS-CoV-2 in patients recovered
   from COVID-19, J. Med. Virol. (2020) jmv.26056. https://doi.org/10.1002/jmv.26056.
- [12] Q. Wang, Y. Zhang, L. Wu, S. Niu, C. Song, Z. Zhang, G. Lu, C. Qiao, Y. Hu, K.-Y. Yuen, Q.
  Wang, H. Zhou, J. Yan, J. Qi, Structural and Functional Basis of SARS-CoV-2 Entry by Using
  Human ACE2, Cell. (2020) S009286742030338X.
- 446 https://doi.org/10.1016/j.cell.2020.03.045.
- L. Premkumar, B. Segovia-Chumbez, R. Jadi, D.R. Martinez, R. Raut, A. Markmann, C.
  Cornaby, L. Bartelt, S. Weiss, Y. Park, C.E. Edwards, E. Weimer, E.M. Scherer, N. Rouphael,
  S. Edupuganti, D. Weiskopf, L.V. Tse, Y.J. Hou, D. Margolis, A. Sette, M.H. Collins, J.
- 450 Schmitz, R.S. Baric, A.M. de Silva, The receptor binding domain of the viral spike protein is

451		an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients, Sci.
452		Immunol. 5 (2020) eabc8413. https://doi.org/10.1126/sciimmunol.abc8413.
453	[14]	C.W. Tan, W.N. Chia, X. Qin, P. Liu, M.IC. Chen, C. Tiu, Z. Hu, V.CW. Chen, B.E. Young,
454		W.R. Sia, YJ. Tan, R. Foo, Y. Yi, D.C. Lye, D.E. Anderson, LF. Wang, A SARS-CoV-2
455		surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike
456		protein-protein interaction, Nat. Biotechnol. (2020). https://doi.org/10.1038/s41587-020-
457		0631-z.
458	[15]	Q.M. Hanson, K.M. Wilson, M. Shen, Z. Itkin, R.T. Eastman, P. Shinn, M.D. Hall, Targeting
459	[=0]	ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug
460		repurposing screen of an AlphaLISA proximity assay, Biochemistry, 2020.
461		https://doi.org/10.1101/2020.06.16.154708.
462	[16]	X. Xie, A. Muruato, K.G. Lokugamage, K. Narayanan, X. Zhang, J. Zou, J. Liu, C. Schindewolf,
463		N.E. Bopp, P.V. Aguilar, K.S. Plante, S.C. Weaver, S. Makino, J.W. LeDuc, V.D. Menachery,
464		PY. Shi, An Infectious cDNA Clone of SARS-CoV-2, Cell Host Microbe. 27 (2020) 841-
465		848.e3. https://doi.org/10.1016/j.chom.2020.04.004.
466	[17]	Davide Giavarina, Understanding Bland Altman analysis, Biochem. Medica. 25 (2015) 141-
467		151. https://doi.org/10.11613/BM.2015.015.
468	[18]	N.Ö. Doğan, Bland-Altman analysis: A paradigm to understand correlation and agreement,
469		Turk. J. Emerg. Med. 18 (2018) 139–141. https://doi.org/10.1016/j.tjem.2018.09.001.
470	[19]	N.A. Obuchowski, J.A. Bullen, Receiver operating characteristic (ROC) curves: review of
471		methods with applications in diagnostic medicine, Phys Med Biol. (2018) 29.
472	[20]	C.T. Nakas, C.T. Yannoutsos, Ordered multiple-class ROC analysis with continuous
473		measurements, Med. Stat. 23 (November 30) 3437–49. https://doi.org/10.1002/sim.1917.
474	[21]	P. Schober, C. Boer, L.A. Schwarte, Correlation Coefficients: Appropriate Use and
475		Interpretation, Anesth. Analg. 126 (2018) 1763–1768.
476		https://doi.org/10.1213/ANE.000000000002864.
477	[22]	J.D. Rights, S.K. Sterba, Quantifying explained variance in multilevel models: An integrative
478		framework for defining R-squared measures, Psychol. Methods. 24 (n.d.) 309–338.
479		https://doi.org/10.1037/met0000184.
480	[23]	J.D. Rights, S.K. Sterba, A framework of R-squared measures for single-level and multilevel
481		regression mixture models, Psychol. Methods. 23 (n.d.) 434–457.
482		https://doi.org/10.1037/met0000139.
483	[24]	J.D. Rights, S.K. Sterba, New Recommendations on the Use of R-Squared Differences in
484		Multilevel Model Comparisons, Multivar. Behav. Res. 55 (n.d.) 568–599.
485	[25]	L.A. Jackson, E.J. Anderson, N.G. Rouphael, P.C. Roberts, M. Makhene, R.N. Coler, M.P.
486		McCullough, J.D. Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers, A. McDermott, B.
487		Flach, N.A. Doria-Rose, K.S. Corbett, K.M. Morabito, S. O'Dell, S.D. Schmidt, P.A. Swanson,
488		M. Padilla, J.R. Mascola, K.M. Neuzil, H. Bennett, W. Sun, E. Peters, M. Makowski, J. Albert,
489		K. Cross, W. Buchanan, R. Pikaart-Tautges, J.E. Ledgerwood, B.S. Graham, J.H. Beigel, An
490		mRNA Vaccine against SARS-CoV-2 — Preliminary Report, N. Engl. J. Med. 383 (2020)
491		1920–1931. https://doi.org/10.1056/NEJMoa2022483.
492	[26]	A. Lombardi, G. Bozzi, R. Ungaro, S. Villa, V. Castelli, D. Mangioni, A. Muscatello, A. Gori, A.
493		Bandera, Mini Review Immunological Consequences of Immunization With COVID-19

- 494 mRNA Vaccines: Preliminary Results, Front. Immunol. 12 (2021) 657711.
- 495 https://doi.org/10.3389/fimmu.2021.657711.
- 496 [27] U. Sahin, A. Muik, E. Derhovanessian, I. Vogler, L.M. Kranz, M. Vormehr, A. Baum, K.
- 497 Pascal, J. Quandt, D. Maurus, S. Brachtendorf, V. Lörks, J. Sikorski, R. Hilker, D. Becker, A.-
- 498 K. Eller, J. Grützner, C. Boesler, C. Rosenbaum, M.-C. Kühnle, U. Luxemburger, A. Kemmer-
- Brück, D. Langer, M. Bexon, S. Bolte, K. Karikó, T. Palanche, B. Fischer, A. Schultz, P.-Y. Shi,
  C. Fontes-Garfias, J.L. Perez, K.A. Swanson, J. Loschko, I.L. Scully, M. Cutler, W. Kalina, C.A.
- 500 C. Fontes-Garfias, J.L. Perez, K.A. Swanson, J. Loschko, I.L. Scully, M. Cutler, W. Kalina, C.A. 501 Kyratsous, D. Cooper, P.R. Dormitzer, K.U. Jansen, Ö. Türeci, COVID-19 vaccine BNT162b1
- 502 elicits human antibody and TH1 T cell responses, Nature. 586 (2020) 594–599.
- 503 https://doi.org/10.1038/s41586-020-2814-7.
- E.J. Anderson, N.G. Rouphael, A.T. Widge, L.A. Jackson, P.C. Roberts, M. Makhene, J.D.
  Chappell, M.R. Denison, L.J. Stevens, A.J. Pruijssers, A.B. McDermott, B. Flach, B.C. Lin, N.A.
  Doria-Rose, S. O'Dell, S.D. Schmidt, K.S. Corbett, P.A. Swanson, M. Padilla, K.M. Neuzil, H.
  Bennett, B. Leav, M. Makowski, J. Albert, K. Cross, V.V. Edara, K. Floyd, M.S. Suthar, D.R.
  Martinez, R. Baric, W. Buchanan, C.J. Luke, V.K. Phadke, C.A. Rostad, J.E. Ledgerwood, B.S.
  Graham, J.H. Beigel, Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in
  Older Adults, N. Engl. J. Med. 383 (2020) 2427–2438.
- 511 https://doi.org/10.1056/NEJMoa2028436.
- [29] N. Doria-Rose, M.S. Suthar, M. Makowski, S. O'Connell, A.B. McDermott, B. Flach, J.E.
  Ledgerwood, J.R. Mascola, B.S. Graham, B.C. Lin, S. O'Dell, S.D. Schmidt, A.T. Widge, V.-V.
  Edara, E.J. Anderson, L. Lai, K. Floyd, N.G. Rouphael, V. Zarnitsyna, P.C. Roberts, M.
  Makhene, W. Buchanan, C.J. Luke, J.H. Beigel, L.A. Jackson, K.M. Neuzil, H. Bennett, B.
  Leav, J. Albert, P. Kunwar, Antibody Persistence through 6 Months after the Second Dose
  of mRNA-1273 Vaccine for Covid-19, N. Engl. J. Med. (2021) NEJMc2103916.
  https://doi.org/10.1056/NEJMc2103916.
- [30] J.E. Ebinger, J. Fert-Bober, I. Printsev, M. Wu, N. Sun, J.C. Prostko, E.C. Frias, J.L. Stewart,
  J.E. Van Eyk, J.G. Braun, S. Cheng, K. Sobhani, Antibody responses to the BNT162b2 mRNA
  vaccine in individuals previously infected with SARS-CoV-2, Nat. Med. (2021).
  https://doi.org/10.1038/s41591-021-01325-6.
- [31] X. Chi, R. Yan, J. Zhang, G. Zhang, Y. Zhang, M. Hao, Z. Zhang, P. Fan, Y. Dong, Y. Yang, Z.
  Chen, Y. Guo, J. Zhang, Y. Li, X. Song, Y. Chen, L. Xia, L. Fu, L. Hou, J. Xu, C. Yu, J. Li, Q. Zhou,
  W. Chen, A neutralizing human antibody binds to the N-terminal domain of the Spike
  protein of SARS-CoV-2, Science. (2020) eabc6952.
- 527 https://doi.org/10.1126/science.abc6952.
- [32] L. Liu, P. Wang, M.S. Nair, J. Yu, M. Rapp, Q. Wang, Y. Luo, J.F.-W. Chan, V. Sahi, A.
  Figueroa, X.V. Guo, G. Cerutti, J. Bimela, J. Gorman, T. Zhou, Z. Chen, K.-Y. Yuen, P.D.
  Kwong, J.G. Sodroski, M.T. Yin, Z. Sheng, Y. Huang, L. Shapiro, D.D. Ho, Potent neutralizing
  antibodies against multiple epitopes on SARS-CoV-2 spike, Nature. 584 (2020) 450–456.
  https://doi.org/10.1038/s41586-020-2571-7.
- [33] Y. Cai, J. Zhang, T. Xiao, H. Peng, S.M. Sterling, R.M. Walsh, S. Rawson, S. Rits-Volloch, B.
   Chen, Distinct conformational states of SARS-CoV-2 spike protein, Science. (2020)
   eabd4251. https://doi.org/10.1126/science.abd4251.
- 536
- 537